Purpose: This multicenter phase II study was designed to assess the efficacy of the alternating schedule of tomudex with methotrexate (MTX)/5-fluorouracil (5-FU)/leucovorin (LV) in first-line chemotherapy for metastatic colorectal cancer.
Introduction
In spite of its limited efficacy, 5-fluorouracil (5-FU) is still the mainstay of chemotherapy for colorectal malignancies. In recent years the addition of modulated agents (methotrexate (MTX) or leucovorin (LV) to 5-FU has improved the outcome of treatment of colon cancer, even though an objective clinical response is obtained in no more than 20% of patients with advanced disease [1] .
Recently, new drugs, such as Tomudex, CPT-11 or oxaliplatin, have appeared to be promising. Tomudex is a direct and specific thymidylate synthase (TS) inhibitor [2] . After the first promising results, however, no more than 20% of patients usually achieve a clinical response to this drug [3] . The resistance of the majority of the patients can be explained by mutations or increased levels of TS [4] .
Because the combination of MTX/5-FU works through a different pathway by the inhibition of RNA synthesis, an alternating administration of tomudex and MTX/5-FU could result in increased cytotoxicity. If this were the case, Tomudex could replace the 5-FU infusional part of the hybrid regimen developed by our group [5] . However, the combination of the two regimens could also determine the theoretical risk of an overlap or potenzialization of toxicity, especially hepatotoxicity, leading to significant dose reductions of drugs. An approach which would avoid such an overlap and would make it possibe to design a trial with a full dose of each single agent, is to alternate delivery of the drugs. The aim of this phase II study was therefore to assess the combination of tomudex given every other cycle alternating with the regimen of MTX/5-FU/LV in advanced colorectal cancer.
Patients and methods

Patient selection
Patients with histologically verified unresectable metastatic disease were eligible for the study. The eligibility criteria included: measurable disease, age less than 70 years, performance status (ECOG) 0-2, life expectancy > 3 months, and no serious concomitant disease affecting liver, heart, kidney.
Exclusion criteria were prior chemotherapy, the presence of CNS metastases and severe concomitant non-malignant diseases.
Written informed consent was obtained from all patients, as were Ethics Committee approvals in ac cord with local requirements.
Chemotherapy regimen
All patients were treated with tomudex 3 mg/m 2 and, after two weeks, MTX, 200 mg/m 2 by 30' infusion after hydration with 1500 ml saline solution, followed on day 2 by 5-FU, 600 mg/m 2 and LV, orally, 15 mg for six times every 6 hours, beginning 24 hours after MTX. Cycles were repeated every four weeks. Treatment was to be administered for up to six alternating cycles or until the appearance of disease progression or unacceptable toxicity, or patient refusal.
Assessment of response and toxicity
The primary efficacy end points assessed were the objective response rate and toxicity. Evaluation of response was performed after three alternating cycles, while toxicity was evaluated weekly according to standard WHO criteria [6] , Secondary efficacy end points included response duration and overall survival.
Statistical methods
A two-stage design was used with a minimum of 17 patients and a maximum of 34 patients, so that the trial could be stopped early if the combination did not produce a response rate of at least 40%. The probability that the trial would be stopped early, i.e., two or fewer responses in the first 17 patients, was aproximately 3% if the true response rate was at least 40%. The regimen would have been considered promising if at least 10 responses were achieved in 34 patients. The probability that 10 or more responses would be observed if the true response rate was 40%, was 82% while there was an only 6% probability of observing 10 or more responses if the true response rate was 20% [7] .
Results
From November 1997 to June 1998, investigators from 8 institutions treated 34 advanced colorectal cancer patients with this regimen. The characteristics of the patients are listed in Table 1 .
Tumor response
Objective tumor response was seen in 4 of 34 patients (12%, 95% CI: 0%-22%), with 1 complete response. Fourteen patients had stable disease and sixteen progressed on therapy. The duration of responses was: nine, six, six, and five months. With a median follow up of 18 months, the median progression-free survival was 5 months, and the median survival was 13 months.
Toxicity
A total of 130 cycles of tomudex and 128 of MTX/5-FU/ LV were administered during the study. Hepatotoxicity represented the most common and severe side effect (Table 2 ). In fact it was reported in 13 patients (38%), with four patients presenting grades 3 and 4 hepatic toxicity. Furthermore, of the three patient hospitalizations two were due to hepatic toxicity and the third to neutropenia. Hematological toxicity was mild with only two patients developing grades 3 and 4 neutropenia. No drug-related deaths were reported.
Discussion
Sobrero et al. showed that the mechanism of cell kill by 5-FU differs depending on its mode of administration, whether short-term infusion or continuous infusion [8] . It was hypothesized that combining these two different schedules of administration would result in an enhancement of cytotoxicty of 5-FU [9] . In the clinical setting, sequential MTX/5-FU/LVand 5-FU continuous infusion were chosen as the two components of the combined regimen because they satisfied the concept of scheduleoriented biochemical modulation. In fact, while 5-FU given by continuous infusion inhibits TS, pretreatment of 5-FU with MTX has been shown to enhance the amount of fluorouridine triphosphate incorporated into RNA [5] . A phase II study showed particularly encouraging results in terms of response rate, which were subsequently confirmed in a randomized trial regarding the time to progression and survival [5, 10] .
Tomudex is a direct and specific TS inhibitor, more potent than 5-FU [3, 4] , Because of its convenient dosing schedule of a single i.v. injection once every three weeks, tomudex was thought to be an appropriate replacement for the 5-FU infusional part of the hybrid regimen developed by Sobrero et al. in an attempt to simplify the schedule.
The objective of this multicenter phase II study was to assess the efficacy of the alternating combination of Tomudex with MTX/5-FU/LV in the first-line treatment of metastatic colorectal cancer. With four objective responses, this alternating schedule yielded the disappointing response rate of 12%, much lower than that obtained with the original regimen including 5-FU continuous infusion [5, 10] .
Some aspects of the schedule selected for this study, rather than comprising a failure of the hypothesis of the schedule-oriented biochemical modulation, could explain these disappointing results.
The interval between the drugs could not be optimal: four weeks for each one instead of two weeks for MTX/ 5-FU/LV and three weeks for Tomudex. Better results could have been obtained by using these two regimens sequentially, as first-and second-line treatments and not in an alternating fashion from the beginning, so that the interval between the administration of the same regimen could be the one suggested by previous studies. Furthermore, the combination of MTX/5-FU/LV with Tomudex, even with an alternating regimen, can increase hepatic toxicity, leading to delays or dose reductions, without increasing the activity. Longo et al. showed that Tomudex can enhance 5-FU cytotoxicity, given by bolus when tomudex is given before 5-FU, whereas simultaneous drug exposure or the opposite sequence produced less-than-additive effects [11] . Thus, the alternating administration of the two drugs could result in no advantage but only in a higher incidence of side effects.
In spite of the disappointing results in terms of response rate, the median survival of 13 months could be considered encouraging. However, it might be due to the favourable characteristics of the patients enrolled in this phase II study (26 patients had PS 0-1; two-thirds of patients had liver metastases and about 50% of them had only one metastatic site) rather than to an effect of treatment.
In conclusion, the alternating combination of Tomudex with MTX/5-FU/LV does not seem to be more effective than the original schedule including 5-FU, while toxicity is more severe. In our opinion, this regimen does not deserve further investigation, at least not with this schedule.
